Citations

Clear

9550 citation(s) found for "James, EM".

Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome
Chen, Alex , Pulido, José S. , Tonne, Jason , Metko, Muriel , Thompson, Jill , Sangsuwannukul, Thanich , Chiriboga-Yerovi, Maria P. , Marcano, Rosa M. Diaz , Webb, Mason , Huff, Amanda L. , Moore, Madelyn , Schuelke, Matthew , Appleton, Elizabeth , Melcher, Alan , Vile, Richard G. , Thompson, Jill M , Diaz Marcano, Rosa M , Webb, Mason James , Schuelke, Matthew R , Irshad, Sheeba , Appleton, Elizabeth , Melcher, Alan A , Kendall, Benjamin Luke , Vile, Richard G , Metko, Muriel , Yerovi, Maria Chiriboga , Irshad, Sheeba , Kendall, Benjamin L.

Mayo Clinic

Cancer Immunology Research | August 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF20

10.1158/2326-6066.cir-25-1589 | PMID 42644627 Get It

Abstract T-cell immune tolerance is established in part through the activity of the autoimmune regulator (AIRE) transcription factor in medullary thymic epithelial cells (mTEC) of the thymus. AIRE induces expression of peripheral tissue–specific self-antigens for presentation to naïve T cells to promote activation/deletion of autoreactive T cells. This traditional role of AIRE in mTECs is to prevent autoimmunity. Herein, we demonstrate that tumors mimic the role of AIRE in mTECs to evade immune rejection. We found that AIRE induced a profile of “selfness” at the RNA and protein levels which, when presented on major histocompatibility complexes (MHC), shielded the tumor from inherently self-tolerized T cells. Moreover, we describe an in vivo immunotherapy in which engineered changes in AIRE expression in tumor cells altered their profile of selfness, exposing both AIRE-modified and parental unmodified tumor cells to T-cell attack. Therefore, by resetting the immunologic selfness of cancer cells, this AIRE-mediated immunotherapy (i) converted a highly tolerized T-cell compartment into a tumor-reactive T-cell population; (ii) conferred upon nonimmunogenic tumors de novo sensitivity to immune checkpoint blockade; (iii) removed the need to identify potentially immunogenic tumor-associated antigens as targets for generation of T-cell responses; and (iv) lead to potent T cell–mediated rejection of aggressive, immunologically cold, nonimmunogenic tumors. Patient RNA sequencing data showed that the expression of AIRE predicted response to immune therapies with a strong correlation between AIRE expression and markers of T-cell receptor signaling, suggesting that our studies have therapeutic translational value.
Multiple Sclerosis Misdiagnosis in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy
Mendis, Dinith , Vallamchetla, Saikrishna , Collazo, I. Vanessa Marin , Sandhu, Sukhwinder J.S. , Meschia, James F. , Mendis, Dinith D , Vallamchetla, Sai Krishna , Marin Collazo, Iris V , Sandhu, Sukhwinder S , Meschia, James F

Mayo Clinic

Neurology Genetics | August 26, 2026 | Volume: 12 | Issue: 5 | Pages: No page available

10.1212/nxg.0000000000200430 | PMID 42689243 Get It

Neuromuscular Ultrasound and Electrophysiologic Correlation of Median Mononeuropathy at the Wrist in Symptomatic Hereditary Transthyretin Amyloidosis
Kopacz, Kira S., Boon, Andrea J. , Luetmer, Marianne T. , Laughlin, Ruple S. , Putko, Brendan , Litchy, William J. , Meiling, James B. , Meiling, James B , Kopacz, Konrad, Pinto, Marcus Vinícius , Putko, Brendan Nicholas , Mauermann, Michelle L.

Mayo Clinic

Journal of Clinical Neurophysiology | August 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/wnp.0000000000001293 | PMID 42640980 Get It

Purpose: Hereditary transthyretin amyloidosis (ATTRv) is a progressive multisystem disease in which median mononeuropathy at the wrist (MNW) is common and often precedes systemic involvement. Nerve conduction studies (NCS) have historically been the gold standard for MNW, but neuromuscular ultrasound (NMUS) is complementary. The aim of this study was to compare NMUS with electrodiagnostic (EDX) testing for the diagnosis of MNW in patients with symptomatic ATTRv. Methods: A retrospective review was performed of patients 18 years and older with ATTRv confirmed by genetic testing who underwent both EDX testing and NMUS of the median nerve between 2019 and 2025. Demographic, NMUS, and EDX data were collected. Results: Data from 15 upper limbs in 10 patients were analyzed. Median nerve cross‐sectional area at the wrist was significantly greater than reference values ( P = 0.041). MNW was identified in 80% of wrists by NMUS and 100% by NCS, with no significant difference between modalities. Median nerve cross‐sectional area at the wrist did not significantly correlate with MNW severity determined by NCS ( r = −0.018; P = 0.941) or with any NCS parameters (all P > 0.080). Concurrent polyneuropathy was diagnosed in 60% of patients, but there was no association between polyneuropathy and MNW detection by either modality ( P > 0.197). Conclusions: NMUS and NCS demonstrate comparable diagnostic accuracy for MNW in ATTRv. Given its noninvasive nature and efficiency, NMUS may serve as an adjunct to classic EDX testing in this population.
T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia
Noll, Julia Han , Dersh, Devin , Li, Jiang Yuan, Hemani, Humza , Lavorando, Maya, Bartoszek, Robert, Amses, Kevin R. , Jain, Ankita , Minehart, Janna , Shestov, Max A, Camerini, Elena , Loren, Alison W., Woyach, Jennifer A. , Goronzy, Jorg Josef, Kater, Arnon P. , Porter, David L., Bushman, Frederic D, Levine, Bruce L. , June, Carl H. , Long, Meixiao, Weng, Nan‐ping , Diorio, Caroline, Ramirez-Fernandez, Angel , Paruzzo, Luca , Camerini, Elena , Peters, Fleur S , Huang, Xiao , Woyach, Jennifer A , Kater, Arnon P , Ruella, Marco , Byrd, John C , Schuster, Stephen J , Siegel, Donald L , Levine, Bruce L , June, Carl H , Frey, Noelle V , Cohen, Adam D , Garfall, Alfred L , Long, Meixiao , Maus, Marcela V , Weng, Nan-Ping , Fraietta, Joseph A , Bartoszek, Robert L. , Ho, Matthew , Paruzzo, Luca , Shestov, Max, Loren, Alison W. , Goronzy, Jörg J. , Ruella, Marco , Byrd, John C. , Powell, Daniel J. , Gill, Saar , Porter, David L. , Schuster, Stephen J. , Bushman, Frederic D. , Frey, Noelle V. , Cohen, Adam D. , Garfall, Alfred L. , Diorio, Caroline J.

Mayo Clinic

Blood Journal | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2025032274 | PMID 42636161 Get It

CD19-directed CAR T-cells (CTL019) can produce durable remissions in chronic lymphocytic leukemia (CLL), but therapeutic success depends on whether autologous T-cells expand, persist, and retain cytotoxic function after manufacturing. Failure of CLL T-cells is often attributed to exhaustion, although many dysfunctional CLL T-cells retain inflammatory cytokine production. We tested whether this paradox reflects immunosenescence, an aging-like program defined by costimulatory loss, DNA damage, inflammatory secretion, repertoire restriction, and proliferative arrest. In response-linked preinfusion CTL019 products, nonresponders and short partial responders had higher senescence and senescence-associated secretory phenotype (SASP) programs than the functional-responder group, comprising complete responders and partial responders with transformed disease. These programs were detectable before infusion and became more prominent during manufacture in susceptible products. They tracked with weak in vivo CAR T-cell expansion and were associated with inferior survival. Serum proteomics revealed a circulating, CLL-associated SASP-like inflammatory milieu in nonresponders. Flow cytometry and T-cell receptor (TCR) profiling showed that poor responders carried CD27⁻CD28⁻ and KLRG1⁺ CD8 T-cells at apheresis, lower product CD27, and reduced product TCR diversity. Research-manufactured CAR T-cells from treatment-naïve CLL samples displayed the same state, most prominently in CD4 CAR T-cells, with SA-β-gal, p16, p53, DNA damage, depletion of less-differentiated states, and senescence-enriched transcriptomes. Under repeated CD19 stimulation, CLL-derived products reached a proliferative ceiling, and p53-high products lost cytotoxic reserve. Ibrutinib improved proliferative fitness, attenuated senescence-associated features and SASP output in paired patient and direct-exposure assays, and enhanced CAR T-cell expansion in an ibrutinib-resistant CLL model. Together, these data identify immunosenescence as a measurable and functionally consequential barrier to CAR T-cell efficacy in CLL and a candidate for therapeutic modulation.
A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
Choudhury, Atish D. , Zhong, Caiwei , Xie, Wanling , Kochupurakkal, Bose , Wu, Peter I-Fan , Riaz, Irbaz Bin , Liu, Ruolin , Yang, David D. , Folefac, Edmund , Lee, Daniel , McKay, Rana R. , Pace, Amanda F. , Adalsteinsson, Viktor A. , Kunos, Charles A., Gore, Steven D. , Das, Biswajit , Taplin, Mary‐Ellen , Kochupurakkal, Bose S , Parikh, Mamta , Einstein, David J , Kessler, Elizabeth , Mayer, Tina , McKay, Rana R , Pace, Amanda , Mouw, Kent W , Chen, Li , Adalsteinsson, Viktor A , Van Allen, Eliezer M , Kunos, Charles , Gore, Steven D , Das, Biswasjit , D'Andrea, Alan , Taplin, Mary-Ellen , Shapiro, Geoffrey I , Choudhury, Atish D , Riaz, Irbaz B , Xie, Wanling , Wu, Peter I-Fan , Mouw, Kent W. , D’Andrea, Alan D. , Shapiro, Geoffrey I.

Mayo Clinic

Cancer Research Communications | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/2767-9764.crc-26-0488 | PMID 42636061 Get It

Abstract Purpose: Inhibitors of the Ataxia telangiectasia and Rad3-related (ATR) protein kinase, a critical component of the DNA damage repair response, have synergistic anti-cancer activity with platinum compounds in preclinical models. We therefore conducted a Phase 2 study of the ATR inhibitor berzosertib+carboplatin vs. docetaxel+carboplatin in metastatic castration-resistant prostate cancer. Patients and Methods: Patients previously treated with at least one androgen receptor pathway inhibitor and taxane underwent mandatory biopsy and were randomized 1:1 to receive Arm A (docetaxel 60 mg/m2+carboplatin AUC4 day 1; or carboplatin AUC5 if not a docetaxel candidate) or Arm B (berzosertib 90 mg/m2 days 2,9+carboplatin AUC5 day 1) every 21 days. The primary endpoint was overall response rate (ORR; ≥50% PSA decline or radiographic response). Results: Of 73 randomized patients, 65 received protocol treatment: 34 on Arm A (26 docetaxel+carboplatin; 8 carboplatin alone) and 31 on Arm B. Thirteen patients (38%) in Arm A and 20 (65%) in Arm B had ≥Grade 3 treatment-related adverse events (TrAEs). ORR was 15% in Arm A (5/34; 5/26[19%] with docetaxel+carboplatin) and 0% in Arm B (0/31). At interim analysis after 65 of planned 130 patients were treated, enrollment was halted due to futility. Homologous recombination repair deficiency status from tissue and blood did not correlate with clinical outcomes, but ATM-deficiency or high levels of phoshpo-KAP1 detected in tissue was associated with clinical benefit across both arms of the trial. Conclusions: Berzosertib+carboplatin demonstrated lower ORR and more frequent ≥grade 3 TrAEs compared to docetaxel+carboplatin in this heavily pre-treated, biomarker-unselected population. NCT03517969
The Association of Flavin Mononucleotide and Lactate During Normothermic Regional Perfusion with Post-Transplant Liver Outcomes: An Exploratory Study
Fischer, R , Cywes, Claire , Ong, Olivia , Muñoz, Nicolás , Din, Sardar, Ibeabuchi, Tobenna , Brown‐Soler, Isabela , Mahmud, Nadim , Cederquist, K., Smith, Georgeine, Benko, Stephanie , Wehrle, Chase J. , Sonnenberg, Elizabeth M. , Gazala, Samir Abu , Markmann, James F. , Olthoff, Kim M. , Shaked, Abraham , Vyas, Frederick, Sellers, Marty T. , Jonge, Jeroen de , Sun, Keyue , Schlegel, Andrea , Abt, Peter L. , Fischer, Raphaël M J , Levine, Matthew H , Abu-Gazala, Samir , Markmann, James F , Olthoff, Kim M , Shaked, Abraham , Sellers, Marty , de Jonge, Jeroen , Sun, Keyue , Schlegel, Andrea , Abt, Peter L , Ong, Olivia , Din, Sardar Wali , Vyas, Frederick

Mayo Clinic

Medicina | August 24, 2026 | Volume: 62 | Issue: 9 | Pages: 1622

10.3390/medicina62091622 | PMID 42796229 Get It

Background and Objectives: Normothermic regional perfusion (NRP) is an effective technique to improve recipient outcomes. However, no valid methods for determining liver viability exist. Identifying relevant biological markers with clinical correlation to liver viability and recipient clinical outcomes is imperative to improve decision-making. Materials and Methods: Fifty-four donors undergoing NRP and their recipients were included. FMN was measured at the start, 1 h, and end of NRP. Lactate was measured at the start, 30, 60, and 90 min of NRP. Primary outcomes were early allograft function using the early allograft dysfunction (EAD) criteria and the model for early allograft function (MEAF). Secondary outcomes included the association with donor warm ischemia time (DWIT), stratified by 30 min. Spearman’s rho assessed correlations. Results: Forty (74%) livers were transplanted, with 5 (12.5%) recipients developing EAD and the mean MEAF score was 3.13 (1.49). FMN at all time points was significantly greater in the EAD group compared to the non-EAD group and was significantly correlated with the MEAF score (Peak FMN: rho = 0.507, p = 0.001). FMN during perfusion did not differ between DWIT < and ≥30 min. Lactate levels were similar across all groups and did not discriminate for adverse allograft outcomes. However, lactate levels during perfusion were higher in the DWIT ≥ 30 min group. Conclusions: These findings suggest that during NRP, elevated FMN, but not lactate, is associated with early allograft function.
Performance of general-population breast cancer risk prediction models in an international consortium
Brantley, Kristen D. , Ahearn, Thomas U, Norton, Emily , MacInnis, Robert, Palmer, Julie R, Vachon, Celine M, Beane-Freeman, Laura, Frost, Reuben, Zirpoli, Gary, Neuhouser, Marian L, Barnett, Matthew, Teras, Lauren R, Patel, Alpa V, Bodelon, Clara, Spielfogel, Emma S. , Kirsh, Victoria A. , Langseth, Hilde , Milne, Roger L, Haiman, Christopher, Scott, Christopher G, Eliassen, A. Heather, Rosner, Bernard, Willett, Walter C, Chen, Yu, Wu, Fen , Zheng, Wei, Long, Jirong, O'Brien, Katie M, Sandler, Dale P, Linet, Martha S. , Anderson, Garnet, Larson, Joseph C. , Lee, I-Min, Chatterjee, Nilanjan, Kraft, Peter, Brantley, Kristen D , Kirsh, Victoria A , Ahearn, Thomas U. , Norton, Emily L., Palmer, Julie R. , Fortner, Renée T. , Vachon, Celine M. , González, Amy Berrington de , Bertrand, Kimberly A. , Zirpoli, Gary , Barnett, Matthew J , Teras, Lauren R. , Hodge, James M. , Patel, Alpa V , Bodelón, Clara , Lacey, James V. , Rohan, Thomas E. , Tsuruda, Kaitlyn M. , Milne, Roger L , Rosner, Bernard, Willett, Walter C. , Romanos-Nanclares, Andrea , Zheng, Wei , Long, Jirong, O’Brien, Katie M. , Sandler, Dale P. , Kitahara, Cari M. , Anderson, Garnet L. , Lee, I-Min, García‐Closas, Montserrat , Chatterjee, Nilanjan

Mayo Clinic

No container title available | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.20.26360899 Get It

Background: Several breast cancer (BC) risk prediction models have been developed to provide personal risk assessments. Though individually validated, their performance has not been systematically evaluated across a wide range of populations or ages. Methods: We harmonized individual-level baseline questionnaire data and incident BC diagnoses from 21 cohorts from North America, Europe, and Australia participating in the Breast Cancer Risk Prediction Project. Five-year absolute risk of invasive BC was estimated for five established risk prediction models using classical risk factors only. Discrimination was evaluated by area under the curve (AUC). Calibration was assessed using average and risk-decile specific expected to observed (E/O) ratios. Performance metrics were meta-analyzed across cohorts and models. Metaregression tested associations between cohort characteristics and performance metrics. Results: This analysis included 1,595,977 women aged 20-75 years, enrolled in studies between 1976-2015, with 19,062 (1.2%) invasive BC cases ascertained within 5 years from exposure assessment. Age-adjusted AUCs were similar across models and cohorts (pooled AUCs by model: 0.57-0.58), while E/O ratios varied substantially (pooled E/O ratios by model: 0.83-1.25). Overestimation was common among predicted high-risk individuals (>3%). No appreciable differences in model performance by cohort age, birth year, race, and variable missingness emerged. Calibration improved after assigning race-specific incidence rates. Conclusion: Existing BC risk prediction models provided similar risk discrimination across multiple cohorts, although there was overestimation of risk for high-risk individuals. Performance variation across cohorts was not driven by specific characteristics, which supports development of a unified risk model for diverse populations that leverages appropriate incidence rates.
Older Age, STAG2 , and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents
Warraich, Momna , Kumar, Sudhesh , Fatima, Mahnoor , McCullough, Kristen , Al‐Kali, Aref , Begna, Kebede H. , Mangaonkar, Abhishek A. , Saliba, Antoine N. , Matin, Aasiya , Litzow, Mark R. , Patnaik, Mrinal M. , Pardanani, Animesh , Foran, James M. , Sproat, Lisa, Khera, Nandita , Tefferi, Ayalew , Gangat, Naseema , Saliba, Antoine N. , Alkhateeb, Hassan B , Mangaonkar, Abhishek A. , Saliba, Antoine N , Matin, Aasiya , Litzow, Mark R. , Hogan, William J , Shah, Mithun V , Patnaik, Mrinal , Pardanani, Animesh , Foran, James M , Khera, Nandita , Tefferi, Ayalew , Gangat, Naseema , McCullough, Kristen B , Saliba, Antoine N , Alkhateeb, Hassan B. , Hogan, William J. , Shah, Meera

Mayo Clinic

American Journal of Hematology | August 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70480 | PMID 42633550 Get It

ABSTRACT Venetoclax (Ven) plus hypomethylating agents (HMA) is standard frontline therapy for newly diagnosed AML (ND‐AML) patients unfit for intensive chemotherapy and is also considered in younger, fit patients. However, consolidation with allogeneic stem cell transplant (ASCT) is often required to secure durable remission. The current study examines posttransplant outcomes in patients with ND‐AML treated with frontline Ven‐HMA who subsequently underwent ASCT. A total of 111 ND‐AML patients (58% male, 60% secondary/therapy‐related, median age 70 years [range, 37–80]) received a median of 3 cycles of Ven‐HMA. Mutations at the time of diagnosis included RUNX1 (18%), SRSF2 (17%), TP53 (16%), ASXL1 , IDH2 , K/NRAS , TET2 (14% each), STAG2 (11%), DNMT3A (8%). All patients were in CR/CRi at the time of transplant including 88% after Ven‐HMA. Measurable residual disease (MRD) by flow cytometry was detectable in 18/76 (24%) patients. Donors were mostly HLA‐matched unrelated (75%); 51% receiving fludarabine/melphalan conditioning and 67% posttransplant cyclophosphamide. At a median follow‐up of 15 months, 42 (38%) of patients have died and 18 (16%) experienced posttransplant relapse. Median posttransplant survival was not reached (NR), with 1‐, 2‐, 3‐year survival rates of 69%/60%/57%, respectively. On multivariate analysis, age ≥ 65 years, STAG2 mutation ( STAG2 MUT ) , and DNMT3A MUT were associated with superior posttransplant survival. Patients were stratified into low‐ (0–1 point), intermediate‐ (2 points), and high‐risk (3 points); age < 65 years, STAG2 wild type, and DNMT3A wild type, with 3‐year survival rates of 89%, 59%, and 19%, respectively ( p < 0.01). Taken together, age, STAG2 MUT and DNMT3A MUT stratified posttransplant survival in Ven‐HMA treated patients with ND‐AML.
Efficacy and safety of fenfluramine in Dravet syndrome: The impact of patient clinical characteristics
Nabbout, Rima , Sullivan, Joseph , Auvin, Stéphane , Cross, J. Helen , Devinsky, Orrin , Guerrini, Renzo, Knupp, Kelly G. , Perry, Μ. Scott , Sánchez-Carpintero, Rocı́o , Scheffer, Ingrid E., Morita, Diego, Healy, Patrick, Langlois, Mélanie , Lagae, Lieven , Scheffer, Ingrid E. , Gil-Nagel, Antonio , Knupp, Kelly G , Perry, Michael Scott , Sánchez-Carpintero, Rocío , Schoonjans, An-Sofie , Specchio, Nicola , Strzelczyk, Adam , Wheless, James W , Wirrell, Elaine C , Lothe, Amélie , Lagae, Lieven , Auvin, Stéphane , Devinsky, Orrin , Cross, Helen J , Scheffer, Ingrid E , Gil‐Nagel, António , Guerrini, Renzo , Specchio, Nicola , Wheless, James W. , Wirrell, Elaine , Morita, Diego A. , Langlois, Mélanie

Mayo Clinic

Epilepsia Open | August 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi4.70340 | PMID 42632015 Get It

Abstract Objective To assess the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS) stratified by age, number of previously attempted antiseizure medications (ASMs), and SCN1A pathogenic variant status. Methods In this post hoc analysis, data from three randomized controlled trials (RCTs) in patients with DS (2–18 years) were pooled and stratified by age (<4; ≥4 years), number of previous ASMs (1–3; 4–6; ≥7), and SCN1A pathogenic variant status ( SCN1A +; SCN1A −). Stratified groups were assessed and compared with the pooled placebo group (change in monthly convulsive seizure frequency [MCSF], longest convulsive seizure‐free interval, and Clinical Global Impression–Improvement [CGI–I] scale scores rated by parents/caregivers and investigators), and safety (treatment‐emergent adverse events [TEAEs]: frequency, days to onset, and proportion resolved). Results Among 348 patients included in the RCTs, 216 were randomized to fenfluramine (0.7 mg/kg/day, n = 88; 0.4 mg/kg/day [with stiripentol], n = 43; 0.2 mg/kg/day, n = 85) and 132 to placebo. Compared with placebo, fenfluramine treatment (all doses combined) resulted in greater MCSF reductions, greater increases in longest convulsive seizure‐free intervals, and a higher proportion of parents/caregivers and investigators reporting clinically meaningful improvement (“Much Improved”, “Very Much Improved”) on CGI–I scores across all stratified groups. CGI–I scores were consistent across fenfluramine doses in most stratified groups, but patients with the fewest number of previous ASMs had the greatest frequency of clinically meaningful improvement on investigator‐rated CGI–I scores. Safety outcomes were similar across all strata. Most TEAEs resolved by end‐of‐study. Significance Fenfluramine treatment was associated with improved seizure outcomes and global functioning compared with placebo regardless of age, number of previous ASMs, and SCN1A status in patients with DS. Fenfluramine was well‐tolerated; no new safety signals were identified. Further studies with larger sample sizes (including adults) and a priori inferential analyses of stratified groups are warranted. Plain Language Summary Patients with Dravet syndrome struggle with seizures and everyday life. In three studies, patients aged 2–18 years received fenfluramine or placebo (sugar pill). Fenfluramine lowered seizures without many side effects. Researchers combined results from these studies to see how fenfluramine worked in different patient groups based on age, number of previous medications, and a gene called SCN1A . They looked at seizure reduction and whether doctors felt patients had improved. In all groups, fenfluramine worked better than placebo, with similar side effects. Researchers believe fenfluramine helped these patients, but some groups were small, so these results need to be confirmed.
Acrylate Patch Testing for Allergic Contact Dermatitis Over 28 Years: Hierarchical Clustering for Subgroup Analysis and Computational Optimization for Patch Test Selection
Colquitt, JennaKay , Yiannias, James A. , Davis, Mark D.P., Hall, Matthew R., Youssef, Molly J. , Yang, Yul W. , Colquitt, JennaKay , Davis, Mark D.P.

Mayo Clinic

Dermatitis® | August 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/17103568261479501 | PMID 42629958 Get It

Background: Acrylate allergy is rising, with many patients showing patch test positivity to multiple acrylates. Understanding acrylate sensitivity can guide avoidance and optimize screening. Objectives: To quantify acrylate patch test positivity, define subgroups using hierarchical clustering, and algorithmically optimize acrylate patch testing series. Methods: We conducted a retrospective review of 27 acrylate allergens patch tested at 3 Mayo Clinic sites (Arizona, Florida, Minnesota) from 1997 to 2024; 14 had ≥1% positivity. Pairwise copositivity rates were background-corrected and analyzed using hierarchical clustering, followed by computational optimization for patch test screening. Results: Among 17,148 patients, 90,818 tests yielded 1,557 positives (1.71%). Most frequent positive reactions were 2-hydroxyethyl acrylate 0.1% (HEA, 5.4%), 2-hydroxypropyl methacrylate 2% (HPMA, 5.0%), and 2-hydroxyethyl methacrylate 2% (HEMA, 4.6%). Clustering revealed 2 general subgroups, with ethyl cyanoacrylate 10% (ECA) showing minimal copositivity to other acrylates. Optimization analysis for screening showed that one allergen (HEMA) captured 49.4% of sensitized patients; 2 (HEMA + ECA) captured 72.2%. Four allergens, including HEMA, ECA, HEA, and diethylene glycol diacrylate 0.1% (DEGDA), captured >90%, and a 7-allergen series captured 100%, with no higher yield from additional acrylates in standard screening. Conclusions: Acrylate allergy is heterogeneous, comprising 2 subgroups, with cyanoacrylates co-reacting separately. Algorithm-guided series refinement improves diagnostic efficiency by prioritizing high-yield allergens for screening while minimizing unnecessary testing.